Rose McNulty

Guideline-directed medical therapy used with remote monitoring can potentially reduce hospitalization in patients with heart failure with ejection fraction.

Sophia Humphreys, PharmD, MHA, BCBBS, discusses common barriers to cancer therapy and how care teams can assist patients in navigating them.

The case shows how such cardiac involvement can mimic neurologic disease and demand complex, multidisciplinary management.

Researchers have developed a machine learning model that reliably predicts pulmonary hypertension (PH) risk in patients with chronic kidney disease (CKD).

Individuals with both low incomes and health problems were more likely to gain employment when covered by Medicaid.

Bariatric surgery halves mortality and reduces liver, heart, and kidney complications in steatotic liver disease vs nonsurgical care.

Nerandomilast slowed disease progression at 2 doses compared with placebo among US participants in the trial.

The study underscores the importance of repeat testing in cases where myelin oligodendrocyte glycoprotein immunoglobulin G tests are borderline.

Despite improved selectivity, real-world data point to persistent cardiovascular challenges even with next-generation BTKi therapies.

A national analysis of CDC data over 25 years revealed persistent sex, racial, and regional disparities in pneumonia and pulmonary fibrosis mortality.

An IPF-derived biomarker profile shows a reproducible association with ILD risk across three RA cohorts.

Nicoletta Colombo, MD, PhD, of the University of Milan-Bicocca, discussed the rationale behind paclitaxel with bevacizumab and pembrolizumab in ovarian cancer.

There is a significant link between chronic spontaneous urticaria and cardiovascular disease risk, highlighting the need for routine assessments.

A new population pharmacokinetic and exposure-response analyses shows no added efficacy or safety benefit from higher doses of serplulimab.

Innovative payer approaches and holistic support could help expand GLP-1 use and improve obesity care outcomes, experts claimed.

Hair loss disorder can lead to a significant psychological and emotional burden that warrants more attention, new research suggests.

Aggressive lifestyle and risk factor control after ablation significantly lowers atrial fibrillation recurrence and improves heart health.

Guideline adherence in treating acute lymphoblastic leukemia (ALL) enhances health care resource utilization, especially for adolescent and young adult patients.

Though patients with type 2 diabetes or chronic kidney disease (CKD) face a greater risk of heart failure (HF) following acute myocardial infarction (AMI), patients without those comorbidities also benefit from empagliflozin.

Innovative cancer therapies are transforming treatment landscapes, yet access challenges persist. Experts discuss strategies to enhance patient care and outcomes.

Metabolic intermediates were identified as active participants in fibrosis progression and potential targets for next-generation therapies.

Real-world data suggest metabolic dysfunction-associated steatotic liver disease is also associated with higher all-cause mortality.

Previous research has evaluated PD-1/PD-L1 immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC), but research in the setting of limited-stage disease is sparse.

Radiomic assessment has been used to distinguish multiple sclerosis from similar disorders, and it might also be useful in identifying MS stages and subtypes.

A new analysis suggests links between ZRSR2 loss and JAK2 V617R disease progression are indirect and complex.

Explore the latest advancements in oncology, including biomarkers and targeted therapies, enhancing patient care at Tennessee Oncology and Vanderbilt-Ingram Cancer Center.

Overlapping metabolic mechanisms drive both chronic kidney disease (CKD) and valvular heart disease (VHD), a new review outlined.

Cardiac adverse events were lower among patients taking zanubrutinib compared with ibrutinib in the real-world setting.

Structural and microbial findings point to a potential nasal-brain immune connection in patients with multiple sclerosis (MS).

A multidisciplinary approach that includes addressing social determinants of health reduces time to remission despite higher initial costs.